Biognosys | GenomeWeb


Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.

The firm, which will open a Boston office at the end of Q1, did not disclose the amount raised but said it was in the "mid-single-digit millions" of dollars.

The effort will use Biognosys' HRM method to complement its MALDI-TOF approach to biomarker work, a company official said.

The collaboration is focused on using Biognosys' HRM mass spec technology to facilitate Biodesix's companion diagnostic work.

With sales growing at a double-digit clip, the Swiss proteomics firm is carving out a market for its mass spec-based protein quantitation services.

Biognosys, a swiss proteomics company, said this week that the new version of Spectronaut, its software for analyzing hyper reaction monitoring data, now enables customers automatically generate spectral libraries using search results from Thermo Scientific's Proteome Discoverer platform.

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has developed a new mass spec workflow that, according to company researchers, combines the advantages of data-independent and data-dependent analyses.

Biognosys this week launched Spectronaut 6.0, a new release of its software for the analysis of hyper-reaction monitoring mass spec data.

Biognosys has launched its Proteome-SEQ protein biomarker discovery service, which the company said is intended for quantification of thousands of proteins in parallel across multiple samples.

NEW YORK (GenomeWeb) – Proteomics firm Biognosys said this week that it has licensed a patent from the Swiss Federal Institute of Technology Zurich covering a technology for capture of N-glycans.


In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.